《即日市評》恆指本週跌1,351點 科網股今沽壓重
受科網股跌勢拖累,恆指今日一度挫逾800點。美國2月通脹率升至7.9%創逾40年新高,美股道指及納指昨各跌0.3%及1%,美國證券交易委員會依據《外國公司問責法》(HFCAA)認定了五家在美上市華資公司爲有退市風險的相關發行人,包括百濟神州(06160.HK)等,須提供證據免被除牌,消息觸發在美上市中概股急跌;執筆之時美國十年期國債孳息率升至1.981釐,美匯指數升至98.77,美股道指期貨最新跌20點或0.06%,納指期貨最新升0.04%。內地2月新增人民幣貸款1.23萬億(市場原預期1.45萬億),上證綜指全日倒升13點或0.4%收3,309點,深證成指升0.6%,滬深兩市成交額共1.05萬億人民幣。
恆指低開430點,其後跌幅擴大,曾跌811點一度低見20,079,午後傳出中美雙方監管機構就審計監管合作磋商有望儘快達成共識,大市跌幅收窄,全日跌336或1.6%,收20,553點;國指跌195點或2.7%,收7,060點;恆生科技指數跌189點或4.3%,收4,246點。大市全日成交總額1,906.92億元,滬、深港通南下交易分別淨流入31.39億元及20.98億元人民幣。
恆指今本週累跌1,351點或6.2%、國指本週累跌626點或8.1%、恆生科指本週累跌490.96點或10.4%。俄烏戰事持續,西方國家對俄國進行經濟制裁,國際油價反覆抽升,引發投資者對環球通脹升溫的憂慮。此外,市場亦關注在美上市中概股所面臨美審計監管風險,令於本港作第二上市的股份股價受壓。
【京東績後挫 中概股捱沽】
京東(09618.HK)公佈去年業績後,全日股價跌11%報211.2元。阿裏巴巴(09988.HK)跌5.5%報90.8元。百濟神州(06160.HK)及再鼎醫藥(09688.HK)各跌4.9%及6.3%。百勝中國(09987.HK)跌6%,和黃醫藥(00013.HK)股價挫9.5%。
美國證券交易委員會(SEC)公佈,依據《外國公司問責法》(HFCAA)認定了五家在美上市公司爲有退市風險的相關發行人,包括百濟神州(06160.HK)(BGNE.US)、百勝中國(09987.HK)(YUMC.US)、和黃醫藥(00013.HK)(HCM.US)、再鼎醫藥(09688.HK)(ZLAB.US)及盛美半導體(ACMR.US)。中證監會相關部門負責人對此迴應表示注意到該情況。這是美國監管部門執行《外國公司問責法》及相關實施細則的一個正常步驟。早前已多次就《外國公司問責法》實施表明過態度,指內地尊重境外監管機構爲提高上市公司財務信息質量,加強對相關會計師事務所的監管,但堅決反對一些勢力將證券監管政治化的錯誤做法。
據《財聯社》引述接近內地管人士透露,中美雙方監管機構就審計監管合作的對話和磋商進展比較順利,雙方都展示了願意解決問題的誠意,有望儘快達成共識。
【跌股千二隻 友邦逆市揚】
港股今日市寬轉弱,主板股票的升跌比率爲12比30(上日爲30比12),下跌股份1,290只(跌幅近3%),恆指成份股今日17只股份上升,下跌股份46只,升跌比率爲26比70(上日爲74比23);大市今日錄沽空323.61億元,佔可沽空股份成交額1,607.49億的20.131%(上日爲20.704%)。
友邦(01299.HK)今日股價逆市上揚3%收77.25元。摩根士丹利發表報告指出,友邦去年關鍵財務指標實現正增長,按固定匯率計新業務價值按年增長18%,營運溢利增長6%,股息升8%,全部勝預期。該行指出,公司未來斥100億美元回購股份,令人驚喜,顯示出公司良好的管治及對前景具強大信心。該行給予友邦「增持」評級,目標價124元。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.